Article Figures & Data
Tables
Additional Files
Data Supplement
Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
© 2017 American Academy of Neurology.
Files in this Data Supplement:- e-Tables - PDF
- Figure e-1 - PDF
Coinvestigators
Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
© 2017 American Academy of Neurology.
Files in this Data Supplement:- Coinvestigators - Microsoft Word file
PODCAST
- Candice Delcourt, MD*,
- Shoichiro Sato, MD, PhD*,
- Shihong Zhang, MD, PhD,
- Else Charlotte Sandset, MD, PhD,
- Danni Zheng, PhD,
- Xiaoying Chen, BPharm, BMgt,
- Maree L. Hackett, PhD,
- Hisatomi Arima, MD, PhD,
- Jun Hata, MD, PhD,
- Emma Heeley, PhD,
- Rustam Al-Shahi Salman, MD, PhD,
- Thompson Robinson, MD, PhD,
- Leo Davies, MD,
- Pablo M. Lavados, MD, MPH,
- Richard I. Lindley, MD, PhD,
- Christian Stapf, MD, PhD,
- John Chalmers, MD, PhD,
- Craig S. Anderson, MD, PhD;
- For the INTERACT2 Investigators
- From The George Institute for Global Health and The University of Sydney (C.D., S.S., E.C.S., D.Z., X.C., M.L.H., E.H., R.I.L., J.C., C.S.A.); Royal Prince Alfred Hospital (C.D., L.D., J.C., C.S.A.), Camperdown, Australia; National Cerebral and Cardiovascular Center (S.S.), Osaka, Japan; Department of Neurology (S.Z.), West China Hospital, Sichuan University, Chengdu; Oslo University Hospital (C.S.), Norway; The University of Central Lancashire (M.L.H.), UK; Department of Preventive Medicine and Public Health (H.A.), Faculty of Medicine, Fukuoka University; Center for Cohort Studies (J.H.), Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Division of Clinical Neurosciences (R.A.-S.S.), Centre for Clinical Brain Sciences, University of Edinburgh; Department of Cardiovascular Sciences and NIHR Biomedical Research Unit for Cardiovascular Diseases (T.R.), University of Leicester, UK; Clínica Alemana de Santiago (P.M.L.), Facultad de Medicina Clinica Alemana Universidad del Desarrollo; Facultad de Medicina (P.M.L.), Universidad de Chile, Santiago; Westmead Hospital Clinical School (R.I.L.), Westmead, Australia; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) (C.S.), Département de Neurosciences, Université de Montréal, Canada; and The George Institute China (C.S.A.), Peking University Health Sciences Center, Beijing, China.
- Correspondence to Dr. Anderson: canderson{at}georgeinstitute.org.au
Abstract
Objective: To clarify associations between intracerebral hemorrhage (ICH) location and clinical outcomes among participants of the main phase Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2).
Methods: Associations between ICH sites and poor outcomes (death [6] or major disability [3–5] of modified Rankin Scale) and European Quality of Life Scale (EQ-5D) utility scores at 90 days were assessed in logistic regression models.
Results: Of 2,066 patients included in the analyses, associations were identified between ICH sites and poor outcomes: involvement of posterior limb of internal capsule increased risks of death or major disability (odds ratio [OR] 2.10) and disability (OR 1.81); thalamic involvement increased risks of death or major disability (OR 2.24) and death (OR 1.97). Involvement of the posterior limb of the internal capsule, thalamus, and infratentorial sites were each associated with poor EQ-5D utility score (≤0.7 [median]; OR 1.87, 2.14, and 2.81, respectively). Posterior limb of internal capsule involvement was strongly associated with low scores across all health-related quality of life domains. ICH encompassing the thalamus and posterior limb of internal capsule were associated with death or major disability, major disability, and poor EQ-5D utility score (OR 1.72, 2.26, and 1.71, respectively).
Conclusion: Poor clinical outcomes are related to ICH affecting the posterior limb of internal capsule, thalamus, and infratentorial sites. The highest association with death or major disability and poor EQ-5D utility score was seen in ICH encompassing the thalamus and posterior limb of internal capsule.
ClinicalTrials.gov registration: NCT00716079.
GLOSSARY
- BP=
- blood pressure;
- CI=
- confidence interval;
- EQ-5D=
- European Quality of Life Scale;
- HRQoL=
- health-related quality of life;
- ICH=
- intracerebral hemorrhage;
- IQR=
- interquartile range;
- IVH=
- intraventricular hemorrhage;
- INTERACT2=
- Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial;
- mRS=
- modified Rankin Scale;
- NIHSS=
- NIH Stroke Scale;
- OR=
- odds ratio
The prognosis for recovery from acute intracerebral hemorrhage (ICH) is strongly related to several radiologic criteria. These include hematoma volume and the degree of extension of blood into the ventricles and the subarachnoid space.1,–,3 Infratentorial location of ICH also predicts a higher likelihood of death or dependency.1,4 However, the relationship between specific locations of supratentorial ICH and outcome is poorly understood due in part to varying designs and definitions across studies.5 We examined associations of ICH location with clinical outcomes among participants of the main phase Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2).6
METHODS
Patients.
The INTERACT2 study was a randomized, open, multicenter, controlled trial with blinded outcome assessment conducted between 2008 and 2012.6 A total of 2,839 patients with imaging-confirmed ICH were randomly assigned to receive either early intensive blood pressure (BP)–lowering treatment (<140 mm Hg systolic BP goal) or the contemporaneous guideline-recommended BP management (<180 mm Hg systolic BP goal) within 6 hours of onset. Follow-up was to 90 days.
Standard protocol approvals, registrations, and patient consents.
The study protocol was approved by the appropriate ethics committee at each participating site, and written informed consent was obtained from patients or appropriate surrogates. INTERACT2 is registered with ClinicalTrials.gov (NCT00716079).
Measures.
Demographic and clinical characteristics were recorded upon patient enrollment. CT scans were performed according to standardized techniques (recommended slice thickness: 5–8 mm) at baseline and centrally analyzed for volume and location of ICH and the presence of intraventricular hemorrhage (IVH) extension.
Three neurologists reviewed all CT scans for detailed assessment of sites involved by each ICH. Defined sites were the caudate head, putamen/globus pallidus, thalamus, posterior limb of internal capsule, anterior limb of internal capsule, external capsule, any lobar region, and infratentorial. ICH could involve one or several sites. For small bleeds confined to any site, that site was classified as involved. For 3 well-delimited sites (caudate head, putamen/globus pallidus, and thalamus), involvement was defined as replacement of over one-third of the structure by blood (judgment made by assessor on CT scan axial slices). For the remaining sites, posterior limb of internal capsule, anterior limb of internal capsule, external capsule, any lobar location, and infratentorial any involvement led to these sites being classified as affected. Superficial supratentorial or lobar location was selected when structures other than deep structures (caudate, putamen/globus pallidus, thalamus, internal capsule) were involved. In large volume ICH, where the hemorrhage spanned the hemisphere from the ventricle to the cortex, location was rated as both deep, with affected sites listed, and lobar. ICH were then evaluated for their entire location, which could involve single or multiple sites. The term encompassing has been used to describe common patterns of ICH that involve one or more of the sites defined above.
Outcomes for these analyses were death or major disability as assessed by the modified Rankin Scale (mRS) (death, score of 6; major disability, score of 3–5) and health-related quality of life (HRQoL) as self-assessed by the patient or by a proxy responder using the European Quality of Life Scale (EQ-5D)7 questionnaire at 90 days. The EQ-5D uses a descriptive system defining the state of general health across 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), with respondents rating their assessment of each as having no (score of 1), some or moderate (score of 2), or severe problems (score of 3). A utility score integrating ratings of the 5 dimensions into a single score was calculated by using population-based preference weights obtained from the UK population for each subscale. The utility score expresses HRQoL quantitatively as a fraction of perfect health: a score of 1 represents perfect health, 0 represents death, and negative scores represent health states considered worse than death; a score between 0.8 and 0.9 represents the average score in the general population.8,–,10 Both measures were used in the present analysis.
Statistical analysis.
Baseline characteristics of included and excluded patients were summarized by means and SD for normally distributed variables, medians and interquartile ranges (IQR) for skewed continuous variables, and numbers (%) for categorical variables. Between-group differences were assessed using the χ2 test for categorical variables and the Wilcoxon test for continuous variables. Associations between ICH sites of involvement and death or major disability, poor HRQoL in each domain (grades of some to moderate or severe vs no problems in the corresponding dimensions), and poor overall HRQoL (utility score ≤0.7 [dichotomized by median]) were assessed in multivariable logistic regression models, adjusted for potential confounders. The adjusted variables included age, female sex, China region of recruitment, history of ischemic stroke and diabetes mellitus, medication history of antihypertensives, antithrombotics, and lipid-lowering agents, NIH Stroke Scale (NIHSS) score (≥11 vs <11 [dichotomized by median]), systolic BP, onset to CT time (log-transformed), baseline hematoma volume (log-transformed), IVH, allocation to intensive BP lowering, laterality (left vs right), and proxy response for the HRQoL models. Each individual site (caudate head, putamen/globus pallidus, thalamus, external capsule, anterior limb of internal capsule, posterior limb of internal capsule, lobar, and infratentorial) was included in the multivariable model to identify independent relationships between specific sites and outcome. The same analysis was repeated without adjusting for NIHSS. Also, common patterns of entire ICH encompassing one or multiple sites were included in a multivariable model adjusted for the same variables except individual sites. A standard level of significance (p < 0.05) was used and the data are reported with odds ratios (OR) and 95% confidence intervals (CI). All analyses were performed using SAS software version 9.3 (SAS Institute, Cary, NC).
RESULTS
Among the 2,829 INTERACT2 participants, 2,066 (73%) were included in the mortality and functional outcome analyses with available baseline DICOM format CT and information on outcome (mRS) at 90 days (figure e-1 at Neurology.org). Table 1 shows the baseline characteristics of included and excluded patients; the former had smaller ICH (median 10.7 [IQR 5.6–18.7] mL vs 12.0 [6.3–23.9] mL) and were more likely to answer the EQ-5D questions themselves (fewer proxy responders, indicative of less severe ICH).
Characteristics of Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2) participants included in and excluded from the analyses
Table e-1 shows the most common patterns of ICH. Entire ICH included 56 combinations of possible sites. Of these possible combinations, 42 (75%) were present in fewer than 10 patients, 6 (11%) in between 10 and 50 patients, and 8 (14%) in more than 130 patients (total n = 1,747, 85% of the total population). The most common patterns were putamen/globus pallidus alone (n = 342), thalamus and posterior limb of internal capsule (n = 339), posterior limb of internal capsule, putamen/globus pallidus, and external capsule (n = 236), thalamus alone (n = 181), lobar alone (n = 181), putamen/globus pallidus and posterior limb of internal capsule (n = 177), putamen/globus pallidus and external capsule (n = 153), and infratentorial alone (n = 138).
Table 2 shows associations between ICH sites of involvement and death or major disability at 90 days. In models adjusted for baseline differences, thalamic, lobar, and infratentorial involvement were associated with death: OR 1.97 (95% CI 1.18–3.29), 1.95 (1.21–3.15), and 2.45 (1.09–5.50), respectively. ICH involving the posterior limb of internal capsule was associated with major disability: OR 1.81 (95% CI 1.45–2.26). ICH involving the thalamus, posterior limb of internal capsule, and infratentorial was associated with the composite endpoint of death and major disability: OR 2.24 (95% CI 1.40–3.57), 2.10 (1.65–2.68), and 3.04 (1.68–5.50), respectively. The same model with all the included variables is shown in table e-2.
Multivariable logistic regression analyses for associations between ICH sites of involvement and outcome
For analysis of HRQoL, 251 patients who died within 90 days and 36 without EQ-5D information were excluded, leaving 1,779 patients for analysis of HRQoL (figure e-1). Table 3 shows associations between ICH location and HRQoL. After adjusting for potential confounders, thalamic OR 2.14 (95% CI 1.32–3.48), posterior limb of internal capsule OR 1.87 (95% CI 1.45–2.40), and infratentorial OR 2.81 (95% CI 1.52–5.20) sites were each associated with poor overall HRQoL (utility score ≤0.7). Posterior limb of internal capsule was associated with poor HRQoL across all domains. Thalamic and infratentorial sites were associated with poor HRQoL in the mobility, self-care, and usual activity domains.
Multivariable logistic regression analyses for associations between ICH sites of involvement and health-related quality of life measured by the 5-dimension European Quality of Life scale, by utility score (≤0.7 vs >0.7) and dimension (some/moderate or severe problems vs no problem)
The same model with all the included variables is shown in table e-3. Tables e-2 and e-3 show that death, major disability, and poor HRQoL were also associated with older age, increased baseline neurologic severity (NIHSS), and baseline ICH volume. Similar results were found when the analyses were not adjusted for NIHSS (tables e-4 and e-5).
Table 4 shows associations between the most common patterns of entire ICH and death or disability at 90 days. After adjustment for potential confounders, ICH encompassing the thalamus and posterior limb of internal capsule were associated with death or major disability (OR 1.72 [95% CI 1.14–2.58]) and major disability (2.26 [1.58–3.23]). ICH encompassing the posterior limb of internal capsule and putamen/globus pallidus with or without additional involvement of the external capsule were associated with disability (OR 1.69 [95% CI 1.13–2.54] and 1.52 [1.04–2.21]).
Multivariable logistic regression analyses for associations between the most common entire ICH encompassing one or multiple sites and outcome
Table 5 shows associations between the most common patterns of entire ICH and HRQoL. After adjustment for potential confounders, ICH encompassing the thalamus and posterior limb of internal capsule were associated with poor EQ-5D utility score (≤0.7 [median]; OR 1.71 [95% CI 1.12–2.60]) and poor HRQoL in the self-care, usual activity, and pain/discomfort domains: OR 2.08 (95% CI 1.34–3.22), 2.26 (1.42–3.60), and 1.78 (1.21–2.62), respectively. Thalamic ICH was associated with poor HRQoL in the usual activity and pain/discomfort domains: OR 1.75 (95% CI 1.04–2.95) and 1.58 (1.00–2.49; p = 0.049). Infratentorial ICH was associated with poor HRQoL in the mobility and usual activity domain: OR 1.78 (95% CI 1.02–3.10) and 1.86 (1.06–3.26). ICH encompassing the putamen/globus pallidus, posterior limb of internal capsule, and external capsule were associated with poor HRQoL in the pain/discomfort domain: OR 1.65 (95% CI 1.10–2.47).
Multivariable logistic regression analyses for associations between the most common entire ICH (encompassing one or multiple sites) and health-related quality of life measured by the 5-dimension European Quality of Life scale, by utility score (≤0.7 vs >0.7) and dimension (some/moderate or severe problems vs no problem)
Table e-6 shows the hematoma volume by site of involvement and table e-7 shows the model fit statistics for tables 2 and 3.
DISCUSSION
This secondary analysis of the INTERACT2 study dataset demonstrates strong associations between the location of ICH and clinically relevant, patient-centered outcomes. Any ICH that involves the posterior limb of internal capsule or thalamus increases the risks of death or disability and of disability alone. ICH involving the posterior limb of the internal capsule, thalamus, and infratentorial sites were each associated with poor HRQoL. In particular, involvement of the posterior limb of the internal capsule was strongly associated with poor outcomes across all HRQoL domains. Of the 8 common recognizable patterns of ICH, the striking characteristic is that all of these that involve the posterior limb of internal capsule are associated with major disability. Isolated thalamic hemorrhage and ICH encompassing the thalamus and posterior limb of internal capsule are associated with poor HRQoL. These data indicate that damage to the capsular pyramidal tracts is particularly disabling, while ICH involving the thalamus and posterior fossa are more likely to be fatal. In contrast, ICH confined to a lobar site seems to have a relatively benign prognosis when adjusted for hemorrhage volume. However, this does not necessarily mean that outcome after a capsular ICH is worse than outcome after a lobar ICH, as mean hemorrhage volume in lobar ICH is large by comparison with deep ICH and volume itself is an important predictor of outcome.1 When looking at ICH that involved a lobar site and one or more other sites, there is an increased risk of death. This is likely to reflect the fact that these are extensive ICH spanning from deep structures to the cortex. Finally, the analysis confirms well-recognized associations between older age,11,12 higher neurologic severity, ICH volume, and poor outcomes.1
There is increasing interest in the assessment of HRQoL after stroke, but there has been limited data on its association with ICH in specific brain locations. In the Factor VII for Acute Intracerebral Hemorrhage trial, deep compared to lobar location of ICH was associated with poor HRQoL,13 but no further assessment of anatomical structures was undertaken.
Damage to the posterior limb of the internal capsule on diffusion tensor tractography has been shown to be related to poor motor outcome and to disability in the ischemic stroke literature,14 while ICH in the thalamus has been shown to be associated with higher in-hospital mortality compared to ICH in other supratentorial locations.15 The pyramidal tracts pass through the posterior limb of the internal capsule location16 and pathology affecting motor function has predictable consequences for disability and HRQoL17 related directly to domains of mobility, usual activity, and self-care, and indirectly to the more subjective domains of pain/discomfort and anxiety/depression. Thalamic ICH is prone to leak blood into the ventricles18 and may extend to compress the brainstem with life-threatening consequences. Greater residual neurologic deficit may explain why survivors of ICH involving the posterior limb of internal capsule, thalamus, and infratentorium had worse overall HRQoL compared to those who recover from ICH in other locations. The finding that the domains of pain/discomfort and anxiety/depression showed no significant associations with thalamic involvement and a very weak association for the former with thalamic ICH in the multivariable models is surprising. Strokes in the thalamus have a high incidence of residual sensory disability and are traditionally associated with pain syndromes,19 while lesions of spinothalamic afferents to the posterior thalamus are associated with development of central pain.20 This effect seems small in ICH.
Strengths of our analysis include the assessment of HRQoL in a large group of participants with ICH with rigorous and structured central adjudication of images for determining ICH location. Limitations include selection bias from a clinical trial population where patients with severe ICH were purposefully excluded. From a practical point of view, the excluded patients were those with a very high likelihood of early death, so they might be expected to influence mortality calculations but not necessarily HRQoL outcomes. Another issue is that ICH location was assessed on varying thicknesses of axial slices of brain CT scans, which adds some noise to the data but probably not of sufficient magnitude to bias the observed changes in one particular site over another. There was a small number of infratentorial and lobar ICH, not allowing for further anatomical segmentation of these compartments. Despite the large size of the INTERACT dataset, when individual complete hemorrhage is analyzed the numbers are reduced to the point where less powerful effects no longer reach significance. Again, this affects mortality analysis more than disability for the reasons stated above.
We have shown that specific ICH sites, namely the posterior limb of the internal capsule, thalamus, and infratentorium, are associated with poor HRQoL in survivors. Infratentorial and thalamic involvement by ICH are associated with the greatest risk of death, and internal capsule lesions with the greatest residual disability. It is well-recognized that infratentorial location is a poor prognostic factor. To this, we can now add deep, posterior supratentorial locations involving the thalamus or posterior limb of internal capsule. These data offer additional practical help for clinicians in assessing patients with ICH and counseling patients and families, as well as in planning rehabilitation and developing individualized pathways of care.
AUTHOR CONTRIBUTIONS
C. Delcourt, S. Sato, R.A.-S. Salman, and C.S. Anderson contributed to the concept and rationale for the study. S. Sato, D. Zheng, and H. Arima contributed to data analysis. C. Delcourt, S. Sato, E.C. Sandset, H. Arima, and C.S. Anderson contributed to the interpretation of the results. All authors participated in the drafting and approval of the final manuscript and take responsibility for the content and interpretation of this article.
STUDY FUNDING
The INTERACT2 study was funded by the National Health and Medical Research Council of Australia.
DISCLOSURE
C. Delcourt, S. Sato, S. Zhang, E.C. Sandset, D. Zheng, and X. Chen report no disclosures relevant to the manuscript. M.L. Hackett is a recipient of a National Heart Foundation Future Leader Fellowship, Level 2 (100034, 2014–2017). H. Arima, J. Hata, E. Heeley, and R.A.-S. Salman report no disclosures relevant to the manuscript. T. Robinson is an NIHR Senior Investigator. L. Davies, P.M. Lavados, R.I. Lindley, C. Stapf, and J. Chalmers report no disclosures relevant to the manuscript. C.S. Anderson holds a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship and reports receiving speaker fees from Takeda China and Boehringer Ingelheim and advisory committee sitting fees from Medtronic and Astra Zeneca. Go to Neurology.org for full disclosures.
Footnotes
↵* These authors contributed equally to this work as co–first authors.
Coinvestigators are listed at Neurology.org.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by the University of Edinburgh's RCUK and COAF open access fund.
Supplemental data at Neurology.org
- Received August 2, 2016.
- Accepted in final form January 18, 2017.
- Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan
Gifts:NONE
Funding for Travel or Speaker Honoraria:NONE
Editorial Boards:NONE
Patents:NONE
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:NONE
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for Travel or Speaker Honoraria:NONE
Editorial Boards:NONE
Patents:NONE
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:NONE
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for Travel or Speaker Honoraria:NONE
Editorial Boards:NONE
Patents:NONE
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:NONE
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for Travel or Speaker Honoraria:NONE
Editorial Boards:NONE
Patents:European Stroke Journal, Editorial Board member, 2016-
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:Post-doctoral fellowship - South-Eastern Regional Health Authority 2016-2018 - Grant number: 2015068
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for Travel or Speaker Honoraria:NONE
Editorial Boards:NONE
Patents:NONE
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:NONE
Research Support, Foundations and Societies:The University of Sydney
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for Travel or Speaker Honoraria:NONE
Editorial Boards:NONE
Patents:NONE
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:NONE
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for travel or speaker honoraria:NONE
Editorial Boards:Boehringer Ingelheim, reimbursement for travel expenses
Patents:Cochrane Stroke Group, Associate Editor, 1 year Cochrane Stroke Group, Editorial Board Member, 6 years
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other activities:NONE
Clinical Procedures or Imaging Studies:National Heart Foundation, Future Leader Fellowship 2014- 2017, Level 2 #100034
Research Support, Commercial Entities:NONE
Research Support, Government Entities:Google
Research Support, Academic Entities:National Health and Medical Research Council, Australia Swedish Research Council Framework, Sweden National Institute for Health Research, United Kingdom
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:National Heart Foundation, Australia Cochrane Chest, Heart and Stroke, Scotland
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for Travel or Speaker Honoraria:NONE
Editorial Boards:NONE
Patents:(1) Journal of Hypertension, Editorial Board Member, 2 year, (2) BMC Public Health, Associate Editor, 4 years, (3) Journal of Epidemiology, Associate Editor, 1 year
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:Takeda Pharmaceutical Company
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:NHMRC Project Grant, 1020462, Chief Investigator, 2012- 2016
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for Travel or Speaker Honoraria:NONE
Editorial Boards:NONE
Patents:NONE
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:NONE
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for Travel or Speaker Honoraria:NONE
Editorial Boards:NONE
Patents:NONE
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:(1) The Australian National Health and Medical Research Council, project grant funding 2014-2016 for the Sleep Apnea and cardioVascular Endpoint study. (grant number 1060078) EH was an investigator on the grant.
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for Travel or Speaker Honoraria:NONE
Editorial Boards:NONE
Patents:(1) Cochrane Stroke Group, editor, 2009-present (2) Evidence-based Preclinical Medicine, senior editor, 2014- present (3) Trials, senior editor, 2016-present
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:UK Medical Research Council senior clinical fellowship (G1002605), 2011-2016. British Heart Foundation travel fellowship (FS/13/72/30531), 2013-2014.
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:Commercial (Daiichi Sankyo), Advisory Board. Commercial (Boehringer Ingelheim), Advisory Board.
Funding for Travel or Speaker Honoraria:NONE
Editorial Boards:NONE
Patents:Age and Ageing, Associate Editor, 2003 to 2016
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:Research Council (EPSRC) 2013 (3 Years, Principal Applicant); Diversity in blood flow control of the brain: moving from individual modelling towards personalised treatment of the injured brain (?320,853) NIHR Health Technology Assessment Programme Clinical Trials 2012 (5 years, Co-applicant); Safety and Efficacy of Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke: the TARDIS Randomied Controlled Trial (?3,291,971) NIHR Health Technology Assessment Programme Clinical Trials 2012 (4 years, Co-applicant); Tranexamic acid for hyperacute primary Intracerebral Haemorrhage, TICH-2 (?2,889,221) NIHR Programme Grant 2012 (5 years, Co-Applicant): Bridging the age gap in breast cancer. Improving outcomes for older women. (?1,705,273) NIHR Senior Investigator 2016 (3 years, Principal Applicant): NIHR Senior Investigator. (?45,000)
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:Stroke Association/British Heart Foundation Programme Grant 2012 (5 years, Principal Applicant); Blood Pressure Variability ? Definition, Natural History, Prognosis and Treatment Following Acute Stroke (?878,190) The Stroke Association 2012 (3 years, Principal Applicant); Enhanced Control of Hypertension and Thrombolysis Stroke Trial, ENCHANTED (?202,319) British Heart Foundation 2010 (3 years, Co-applicant); Intermediate Basic Science Research Fellowship: Forecasting brain injury in the virtual patient (?259,268) Stroke Association 2009 (2 years, Principal Applicant); Project Grant: MRI Assessment of Post-Stroke Focal Versus Global Cerebrovascular Autoregulation (?102,332) British Heart Foundation 2008 (3 years, Co-applicant); Project Grant: Safety and tolerability of adding clopidogrel to aspirin and dipyridamole in patients with acute ischaemic stroke or TIA: a randomised controlled trial (?318,932)
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for Travel or Speaker Honoraria:NONE
Editorial Boards:NONE
Patents:NONE
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:NONE
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for travel or speaker honoraria:NONE
Editorial Boards:1. Bayer: Received travel grant by Bayer for the ?andu study. 2. Received speaker honoraria from Bayer
Patents:NONE
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:1. Clinica Alemana, Universidad del Desarrollo: Receives institutional support from Clinica Alemana, Universidad del Desarrollo to perform stroke administration and research.
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:1. Boerhinger Ingelheim: Receives research funding for the ?andu study. 2. Astra Zeneca: Served as national leader of SOCRATES study and receives research funding for this. 3. Bayer: Serves as the National leader of the NAVIGATE ESUS trial.
Research Support, Academic Entities:CONICYT: Recieved research grant for the ?andu proyect.
Research Support, Foundations and Societies:1. Clinica Alemana-Universiad del Desarrollo: Receives academic research support from Cl?nica Alemana for the HEADPOST studies. 2. The George Institute for Global Health. Receives academic research support from TGI for the INTERACT2, ENCHANTED and HEADPOST studies.
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for Travel or Speaker Honoraria:NONE
Editorial Boards:NONE
Patents:I am an Associate Editor for the Australasian Journal on Ageing, not compensated.
Publishing Royalties:NONE
Employment, Commercial Entity:Stroke: The Facts. Lindley RI. Oxford University Press 2008. ISBN 978-0-19-921272-9 Understanding Stroke. Lindley RI. The British Medical Association Family Doctor Series. ISBN: 1 898205 60 4. Published by Family Doctor Publications Ltd in association with the British Medical Association 2000. Second edition 2002. Third Edition 2003. Fourth edition 2005.
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:1) INTERACT: a randomised trial of intensive blood pressure lowering in acute intracerebral haemorrhage. Anderson C, Chalmers J, Wang J, Lindley R. 2) NHMRC (Australia) Project Grant 512402;Chief Investigator 2008-11. 3) NHMRC (Australia) Partnership Grant 569328, Chief Investigator, 2010-2014. 4) NHMRC (Australia) Project Grant APP1004170, Chief Investigator 2011-13. 5) NHMRC (Australia) Project Grant, APP1020462 Chief Investigator, 2012-2015 6) NHMRC (Australia) Project Grant, APP1024440, Chief Investigator, 2012-14 7) NHMRC (Australia) Project Grant, APP1041401, Chief Investigator 2013-6 8) NHMRC (Australia) Project Grant. APP1045391 Chief Investigator, 2013-6 9) NHMRC (Australia) Project Grant,APP1063751 Chief Investigator, 2014-6 10) NHMRC (Australia) Project Grant, APP1101113 Chief Investigator, 2016-8
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for Travel or Speaker Honoraria:NONE
Editorial Boards:NONE
Patents:NONE
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:NIH/NINDS, NS051483-01A1, co-PI, 2006-2014
Research Support, Foundations and Societies:(1) Columbia University New York, USA; (2) University Paris Diderot - Sorbonne Paris Cit?, France
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:NONE
Funding for travel or speaker honoraria:NONE
Editorial Boards:Research grants from Servier for the ADVANCE-ON post trial follow-up study and, and honoraria and travel support from Servier, for speaking about the ADVANCE and ADVANCE-ON studies at Scientific meetings
Patents:Associate Editor for the Journal of Hypertension, from 2011
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:The National Health and Medical Research Council of Australia has awarded me two project grants (1) as Co- Chief Investigator for INTERACT2 for 2008-2011 : Grant number 512402:2008-2011, and (2) as Co-Chief Investigator for ENCHANTED for 2012-17 : Grant Number APP1020462.
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE
Gifts:Astra Zeneca and Medtronic
Funding for travel or speaker honoraria:NONE
Editorial Boards:Receives honoraria and for travel from Takeda China and Boehringer Ingelheim
Patents:Stroke, Cerebrovascular Diseases, International Journal of Stroke
Publishing Royalties:NONE
Employment, Commercial Entity:NONE
Consultancies:NONE
Speakers' Bureaus:NONE
Other Activities:NONE
Clinical Procedures or Imaging Studies:NONE
Research Support, Commercial Entities:NONE
Research Support, Government Entities:NONE
Research Support, Academic Entities:Program grant (1052555), Project grant (1020462) and Fellowship (1081356) support from the National Health and Medical Research Council (NHMRC) of Australia.
Research Support, Foundations and Societies:NONE
Stock/Stock Options/Board of Directors Compensation:NONE
License Fee Payments, Technology or Inventions:NONE
Royalty Payments, Technology or Inventions:NONE
Stock/Stock Options, Research Sponsor:NONE
Stock/Stock Options, Medical Equipment & Materials:NONE
Legal Proceedings:NONE
NONE